The serological responses of 195 multiple sclerosis (MS) patients and 251 controls were tested against 6/94-parainfluenza virus, which was previously isolated from brain tissue of two patients with MS. The hemagglutination-inhibition titers of greater than or equal to 1: 128 were found more frequently in MS patients (21.5%) than in controls (14.0%). However, the geometric mean titers did not differ between these two groups. The present study concludes that a causal relationship of 6/94-virus to MS, based on a specific immune response, is improbable, although it does not exclude the possibility of a pathogenetic significance of the agent in the cases from which the autopsy material was derived.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00312815 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood immunophenotyping of multiple sclerosis patients at diagnosis identifies a classical monocyte subset associated to disease evolution.
Front Immunol
January 2025
Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche U1236, Université Rennes, Etablissement Français du Sang Bretagne, LabEx IGO, Rennes, France.
Introduction: Myeloid cells trafficking from the periphery to the central nervous system are key players in multiple sclerosis (MS) through antigen presentation, cytokine secretion and repair processes.
Methods: Combination of mass cytometry on blood cells from 60 MS patients at diagnosis and 29 healthy controls, along with single cell RNA sequencing on paired blood and cerebrospinal fluid (CSF) samples from 5 MS patients were used for myeloid cells detailing.
Results: Myeloid compartment study demonstrated an enrichment of a peculiar classical monocyte population in 22% of MS patients at the time of diagnosis.
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis.
Front Immunol
January 2025
Department of Neurosciences, University of Padua, Padua, Italy.
Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published.
View Article and Find Full Text PDFInteraction between Th17 and central nervous system in multiple sclerosis.
Brain Behav Immun Health
February 2025
Centre for Infection and Immunity Studies, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, 518107, China.
Image 1.
View Article and Find Full Text PDFMachine learning for refining interpretation of magnetic resonance imaging scans in the management of multiple sclerosis: a narrative review.
R Soc Open Sci
January 2025
University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2GW, UK.
Multiple sclerosis (MS) is an autoimmune disease of the brain and spinal cord with both inflammatory and neurodegenerative features. Although advances in imaging techniques, particularly magnetic resonance imaging (MRI), have improved the process of diagnosis, its cause is unknown, a cure remains elusive and the evidence base to guide treatment is lacking. Computational techniques like machine learning (ML) have started to be used to understand MS.
View Article and Find Full Text PDFBlood level of neurofilament light chain as a biomarker for neurological disorders.
BMJ Med
January 2025
Laboratory Medicine - Neurochemistry, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!